

A quarterly e-News Letter Issue Dec2021;Volume 24

Pharmaware

VISION

To be recognized as a foremost institution imparting quality pharmacy education to aspiring pharmacists with right competencies, attitude, skills and knowledge, for the greater benefit of mankind.

MISSION

To produce highly qualified and motivated graduates possessing fundamental knowledge and soft skills, who can provide sustainable solutions to health care problems.

To develop partnerships with industries, eminent institutes and government agencies in the field of pharmaceutical sciences.

To serve the community, at local, national and international levels, with a deep awareness of our ethical responsibilities towards profession and society.

PROGRAM EDUCATIONAL OBJECTIVES

OUR GRADUATES SHOULD HAVE:-

1. Have quality theoretical knowledge and practical skills on all core and allied fields of pharmaceutical sciences, so that they can face the challenges of the globalized scenario and contribute to the progress of the nation.

2. Enjoy successful careers in all settings of Pharma sector, by engaging themselves in professional development through leadership, communication, skills, teamwork and entrepreneurship.

3. Function ethically and lawfully in professional environment and exhibit good competency in their work culture.

4. Act as a link between healthcare system and community, so as to serve the society by the transmitting their knowledge, with a sense of social responsibility.

5. Participate in l continuing education

ALL INDIA 29TH RANK IN NIRF-2016

AKTU APROVED PHD RESEARCH CENTRE

NBA ACCREDITED (B.PHARM)

Chief Patrons Shri Dinesh Kumar Goel

Shri Akshat Goel

Patrons

Dr. Laxman Prasad Dr D.K. Chauhan Dr. Umesh Kumar Singh Dr. D.R. Somashekar Editor in Chief Dr Monika Sachdeva Editor Dr. Munendra Mohan Varshney Chief Advisory Committee Mr. H. G. Garg Mr. Vipul Goel Faculty Advisory Board Mr. Abhinav Agrawal Dr. Vishwanath Agrahari Dr. Vijay Agarwal Mr. Pankaj Kumar Sharma Dr. Dilip Gupta Dr Manish Mishra Ms. Geetika mehta Mr.Garima tripathi Ms.Rashmi tripathi Ms.Rituparna Palit Ms Avantika Sharma Dr. Neha Krishnarth Dr. M.A. Sheela Ms Archana Gupta Ms Priya Tyagi Ms Rini singhal Ms Chaya chauhan Ms Anjali Singh Ms Anshu Tripathi Ms Kamini Ms Anushka jain Ms. Farhat Student coordinators Adarsh Pathak Ishika Tyagi

COVID SECTION

Omicron: A New variant of Covid-19

On 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO's Technical Advisory Group on Virus Evolution (TAG-VE). This decision was based on the evidence presented to the TAG-VE that Omicron has several mutations that may have an impact on how it behaves, for example, on how easily it spreads or the severity of illness it causes. Here is a summary of what is currently known.

Studies underway: At the present time, WHO is coordinating with a large number of researchers around the world to better understand Omicron. Studies currently underway or underway shortly include assessments of transmissibility, severity of infection (including symptoms), performance of vaccines and diagnostic tests, and effectiveness of treatments. WHO encourages countries to contribute the collection and sharing of hospitalized patient data through the WHO COVID-19 Clinical Data Platform to rapidly describe clinical characteristics and patient outcomes.

Transmissibility: It is not yet clear whether Omicron is more transmissible (e.g., more easily spread from person to person) compared to other variants, including Delta. The number of people testing positive has risen in areas of South Africa affected by this variant, but epidemiologic studies are underway to understand if it is because of Omicron or other factors.

Severity of disease: It is not yet clear whether infection with Omicron causes more severe disease compared to infections with other variants, including Delta. Preliminary data suggests that there are increasing rates of hospitalization in South Africa, but this may be due to increasing overall numbers of people becoming infected, rather than a result of specific infection with Omicron. There is currently no information to suggest that symptoms associated with Omicron are different from those from other variants. Initial reported infections were among university students—younger individuals who tend to have more mild disease—but understanding the level of severity of the Omicron variant will take days to several weeks. All variants of COVID-19, including the Delta variant that is dominant worldwide, can cause severe disease or death, in particular for the most vulnerable people, and thus prevention is always key. Recommended actions for peoples The most effective steps individuals can take to reduce the spread of the COVID-19 virus is to keep a physical distance of at least 1 meter from others; wear a well-fitting mask; open windows to improve ventilation; avoid poorly ventilated or crowded spaces; keep hands clean; cough or sneeze into a bent elbow or tissue; and get vaccinated when it's their turn.

HERBAL INFORMATION CALOTROPIS GIGANTEA, (AAK)

Botanical name: Calotropis gigantia Family: Apocynaceae Kingdom: plantae



Calotropis gigantea, the crown flower, is a species of Calotropis It is a large shrub growing to 4 m (13 ft) tall. It has clusters of waxy flowers that are either white or lavender in colour. Each flower consists of five pointed petals and a small "crown" rising from the center which holds the stamens. The aestivation found in calotropis is valvate i.e. sepals or petals in a whorl just touch one another at the margin, without overlapping. The plant has oval, light green leaves and milky stem. The latex of Calotropis gigantea contains cardiac glycosides, fatty acids, and calcium oxalate. The roots also contain Calotropone.

.USES

It is used in digestive disorders including diarrhea, constipation and stomach ulcers; for painful conditions including toothache, cramps, and joint pain; and for parasitic infections including elephantiasis and worms. Some people use calotropis for syphilis, boils, inflammation (swelling), epilepsy, hysteria, fever, muscular spasm, warts, leprosy, gout, snakebites, and cancer. In inhalation therapy, smoke from the bark is inhaled for coughs, asthma, and to cause sweating.

Marketed Formulations:





1. CALOTROPIS GIGENTIA MOTHER LIQUER

https://www.webmd.com/vitamins/ai/ingredientmono-797/calotropis

STUDENT CORNER

FDA Approved "PreHevbrio" (Vaccine)

Continuous drug discoveries have always been the spinal cord of pharmaceutical and biotechnological researches for various chronic and persistent disorders like Hepatitis B. This atrocious disorder has infected many, putting people at high risk of death from cirrhosis and liver cancer and killing 8,20,000 people each year

One such burning drug discovery is "PreHevbrio" is a 3 antigen Hepatitis B vaccine which is recombinant for the prevention of Hepatits B virus (HBV) infection in adults. This burning discovery is emerging out as a very pragmatic option. It contains three Hepatitis B surface antigens S, Pre-S2 and Pre-S1 HBV and cleared two phases of clinical studies. It is administrated via intramuscular injection as a series of 3 doses on a O-1 and 6 month schedule.

The side effects known till now are severe allergic reaction, injection site pain, headache, fatigue and myalgia. It is founded by VBI Vaccines Inc. and approved by FDA on November 30, 2021. This drug can prove to be very effective and ensure the lives of many to reach the goal of eliminating this soon.

COVEX: Approved VACCINE

The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. As well as reducing the tragic loss of life and helping to get the pandemic under control, introduction of a vaccine will prevent the loss of US\$ 375 billion to the global economy every month. Global equitable access to a vaccine, particularly protecting health care workers and those most-at-risk is the only way to mitigate the public health and economic impact of the pandemic.

The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

The COVAX Global Supply Forecast aims to provide an up-to-date overview of the supply of safe and effective vaccines to the COVAX Facility. Our goal is to offer economies participating in COVAX as much clarity as possible on when we expect the doses we have secured to start arriving. To this end, we provide both a global overview as well as specific regional forecasts. The latest edition of this forecast also includes a detailed overview and analysis of changes from the previous edition (September 2021). There are many uncertainties affecting the supply of COVID-19 vaccines in 2021, not least around manufacturing capacity, export restrictions, regulatory approvals, funding availability,

Anshika Bhardwaj Jhalak Gupta B.Pharm IIIrd Sem

Reference: www.drugs.com, https://www.who.int/initiatives/act-accelerator/covax

NEWS AT A GLANCE

BOOK LAUNCH CEREMONY

RKGIT (Pharmacy) organized Book Launch Ceremony of Text book of medicinal chemistry (Revised Edition) and D.Pharma MCQs authored by Dr Munendra Mohan Varshney (Associate Professor) on 16th Nov.



MOU SIGNED

R.K.G.I.T. (Pharmacy), Ghaziabad signed a MoU with one of the India's leading drug manufacturer in natural medicine on 26th Nov 2021. SCHWABE INDIA plans to develop new products from natural sources. For developing the Pre-formulation, the Firm seeks the expertise of expert through RKGIT(Pharmacy) one of the leading Academic Institute having sophisticated lab facilities and highly intellectual scientific staff join hands with SCHWABE INDIA in developing new formulations on various lifestyle disorders and also in Nutraceutical sector by using Indian natural resources. It is anticipated that the outcome of the results will lead to new vistas in Indian Systems of Medicine, and will be significant towards Atmanirbhar Bharat it a step



CERTIFICATION COUR\$E\$/NPTEL

Vasu Chauhan (M.Pharm Final Year Student) has successfully completed online certification courses of Uppsala Monitoring Centre and Preeti (M.Pharm Final Year) Student has successfully completed online certification courses of NPTEL Online Certification.

MERITORIOUS ACHEIVMENT

RKGIT (Pharmacy) congratulate Ms Kamini (Assistant Professor) on achieving 9.31 CGPA in M.Pharm (Pharmaceutics) Batch 2019-21. She secured 2nd rank in AKTU and awarded silver medal in the convocation held in AKTU, Lucknow on 16th Dec 2021.





Anjanaya Gupta (B.Pharm., 3rd Year student) secured 2nd position in monoact at Noida Rang Mahotsav where he performed Monoact on Terrorism On 30th October 2021, He competed with the students of Delhi University, Jawaharlal Nehru University and other University students.

SPORTS FEST

The two-day Dr Abdul Kalam Sports Fest 2021 was organized by AKTU started at RKGIT Ghaziabad On 22nd& 23rd November 2021. B.Pharm. students, Preeti Dubey (4th Year), Shrishti Pandey (2nd year), Bhawna Adhikari (2nd year) has participated in Kho- Kho event and secured 2nd Position at Dr. A.P.J. Abdul Kalam Sports fest 2021-22 (Zonal Level) held on 22nd - 23 rd November 2021 at RKGIT, Ghaziabad. Students of pharmacy participated as a members of medical team in sports fest playing an important role in providing FIRST AID to all the injured players providing all type of medicament to the injured players to make the proper flow of game.





MR ATTITUDE/MR HAND\$OME

Pragesh Dixit and Parikshit Sachdeva B.Pharm 1st year student has participated in Ramp Walk event of Fresher's party on 11th December 2021 and won the title "Mr. Attitude and "Mr. Handsome". Shweta Gupta of B.Pharm. 1st year also participated in western dance event



BLOOD DONATION CAMP

R.K.G.I.T organized a blood donation camp with Rotary Vardaan Blood Bank on 27th Nov 2021. Many people and students at the college participated in the camp with enthusiasm. Inauguration of the event was done by Dr. Somashekar (Director, R.K.G.I.T. Ghaziabad) and successfully coordinated by Dr. Monika Sachdeva (Principal, R.K.G.I.T. (Pharmacy), Ghaziabad) and Dr Vibhuti (HOD, MBA). The student volunteers who managed this event were Manan K. Goel, Himanshu Sharma, Shivam Gupta, Rohit Kumar. The event was a success and approximately 125 units of blood were collected.



ORIENTATION PROGRAMM

RKGIT (Pharmacy) organized orientation program for FIRSTBATCH of D.Pharm on 11th November, 2021 and for B.pharm and M.Pharm first year students on 12 th November, 2021. Dr Monika Sachdeva, Principal, Dr Umesh Kumar Singh, Director(R&D), in their welcome address motivated the students to be ethical in their dealings and focus on their goals in life. Various career opportunities was discussed by Mr Abhinav Agrawal, Associate Professor and Dean(Academics). Students were also made aware of evaluation scheme and ordinaces followed by BTE UP and AKTU, Lucknow, examining bodies for D.Pharm and B.Pharm, M.Pharm respectively. All faculty members introduced themselves and wished all the students memorable learning experiences during their stay at RKGIT.

PATENT GRANTED/ PUBLISHED

An Innovation German patent (Patent no. 202021105267) Urkunde, by inventors Ms Pankaj Sharma (Assistant Professor), has been granted 15.10.21.

FACULTY ATTENDED FDP/WORK\$HOP

- Dr Neha Krishranarth (Assistant Professor) Participated in five days virtual FDP on the theme of "Research design and methodology" organized by IFTM University, from 22nd Nov to 26th Nov 2021.
- Ms Anushka Jain (Assistant Professor) Presented a paper entitled "Approaches and applications of polymeric micelles as drug delivery system" in two days International Conference on "Advances in Pharmaceutical & Health Sciences" (APHS-2021) organized by KIET Group of Institutions (KIET School of Pharmacy), Ghaziabad in collaboration with CSIR-IITR, Lucknow, India from 7-8 October 2021.
- Ms Anushka Jain(Assistant Professor) Participated and successfully completed AICTE Training and Learning (ATAL) Academy Online Elementary FDP on "Applications of Biotechnological and Analytical Tools in Pharmaceutical Research" from 14.9.21 to 18.9.21 at Meerut Institute of Engineering and Technology.

PUBLICATION\$

- Shubhanjali, Abhinav Agarwal, Late Dr. Sunil Khatak title "Topical Formulations used for the treatment of soft tissue infections" in World Journal of Pharmacy and Pharmaceutical Sciences Vol. 10 Issue 9, 2021.
- Aamir khan, Dilip kumar gupta, Vishwanath Agarhari, title "A review on mucoadhesive drug delivery system with special emphasis on gastric route" in International Journal of All Research Education And Scientific Methods, Vol 9 (10), 2021.
- Yash Agarwal, Avantika Sharma, Munendra Mohan Varshney title "A report on preparation and evaluation of polyherbal facial scrub" in World Journal of Pharmacy and Pharmaceutical Sciences, 10(12), 1045-1053, 2021.
- Vijay Agarwal etal title "Design, Fabrication and Characterization of Esomeprazole Nanocrystals for Enhancing the Dissolution Rate and Stability" in Recent Patents on Nanotechnology, 15, 1-6, 2021.



wishing all the readers HAPPY NEW YEAR 2022

regards Pharmaware Team

For Views and Suggestions Connect epharmaware@gmail.com Raj Kumar Goel Institute of Technology (Pharmacy), 5th KM Stone, Delhi-Meerut Road, Ghaziabad, U.P. 201003, Ph. 9582945609